These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7551266)

  • 1. Clinical investigations of the arrest and reversal of coronary artery disease.
    Farmer JA; Gotto AM
    Coron Artery Dis; 1995 Jun; 6(6):457-65. PubMed ID: 7551266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on lipid-lowering therapy and LDL-cholesterol targets.
    Wiviott SD; Cannon CP
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for new American Diabetes Association Guidelines: are national cholesterol education program goals adequate for the patient with diabetes mellitus?
    Haffner S
    Am J Cardiol; 2005 Aug; 96(4A):33E-36E. PubMed ID: 16098841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Med; 2005 Dec; 118 Suppl 12A():22-7. PubMed ID: 16356804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of subclinical coronary atherosclerosis and National Cholesterol Education Panel guidelines in asymptomatic Brazilian men.
    Nasir K; Santos RD; Roguin A; Carvalho JA; Meneghello R; Blumenthal RS
    Int J Cardiol; 2006 Mar; 108(1):68-75. PubMed ID: 16516700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherosclerotic lesions in humans--plaque stabilization and regression.
    Kritz H; Sinzinger H
    Wien Klin Wochenschr; 1995; 107(18):555-66. PubMed ID: 7483643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid lowering and coronary risk.
    Gotto AM
    Isr J Med Sci; 1996 Jun; 32(6):355-9. PubMed ID: 8682640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy.
    Wiviott SD; Cannon CP
    Curr Opin Lipidol; 2006 Dec; 17(6):626-30. PubMed ID: 17095906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
    Davidson MH; Maki KC; Pearson TA; Pasternak RC; Deedwania PC; McKenney JM; Fonarow GC; Maron DJ; Ansell BJ; Clark LT; Ballantyne CM
    Am J Cardiol; 2005 Aug; 96(4):556-63. PubMed ID: 16098311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of the LDL-/HDL-cholesterol quotient on progression and regression of arteriosclerotic lesions. An analysis of controlled angiographic intervention studies].
    Gohlke H
    Wien Klin Wochenschr; 1992; 104(11):309-13. PubMed ID: 1621390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
    Stone NJ; Bilek S; Rosenbaum S
    Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.
    Clearfield M; Downs JR; Lee M; Langendorfer A; McConathy W; Gotto AM
    Am J Cardiol; 2005 Dec; 96(12):1674-80. PubMed ID: 16360356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.